To determine if FGF21, CK18 and CK18 M30 expression levels in liver were changed along with liver pathological manifestations and apoptosis marker, we examined the markers using immunohistochemistry staining in liver tissues from patients without NAFLD, patients with simple steatosis or with NASH. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.